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status and health preferences were collected longitudi-
nally over three different time periods by the SF-36 and
the linear analog instruments. Only patients with chronic
diseases (n  5000) were included in the present study. A
moving average time series model was made using the
SF-36 components as explanatory variables and the lin-
ear analog scale as the dependent variable. Patient’s age,
gender, comorbidities, and health behavior were used as
covariates. As chronic disease severity may affect perceived
health status and health preference, two different cross-
sections were obtained on basis of high or low chronic
disease score. A random coefficient panel data model was
then used to capture heterogeneity. Model heteroscedas-
ticity was corrected by GARCH modification.
RESULTS: Domains of the SF-36 explained almost 49%
variation in the linear analog scale (Yule Walker estimate
R2  0.5055). All of the domains except “role limitation
due to emotional problem” showed high statistical signif-
icance level (p  0.05) in determining variation in the
LAS. Patient comorbidity also showed statistical signifi-
cance at the same level. Random coefficient model could
not find any statistically significant differences in estima-
tion procedure between patients with high and low num-
bers of chronic diseases. However, education and marital
status were significant predictors.
CONCLUSION: This study extends previous research to
derive a preference based index from the SF-36. This evi-
dence suggests that the SF-36 domains, education, and
marital status are better predictors of the LAS than is se-
verity of chronic disease.
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In spring 1998, the ERIQA project was launched with
the objective of producing guidelines on the use of QoL
data in the drug approval process. A first step led to a
thorough review of existing information.
OBJECTIVE: The purpose of the present study was to re-
view and evaluate the EMEA guidelines, to identify dis-
eases/drugs in which a formal QoL assessment is recom-
mended, identify measures and methods recommended,
and evaluate the reliability of recommendations across
documents.
METHODS: Four types of documents were retrieved in
the EMEA Web site (October 26,1998): notes for guid-
ance, concept papers, position papers, points to consider.
A first review allowed the selection of 105 documents.
The review of titles (by two independent reviewers) led to
the identification of 45 documents likely to contain QoL
recommendations.
RESULTS: Out of these 45 papers, only 12 showed ex-
plicit statements on QoL assessment. There are no docu-
ments directly focused on QoL measures, and few (11)
explicit recommendations on specific diseases/drugs.
QoL measures are often recommended as supportive cri-
teria of efficacy, except in COPD where it is considered
as a primary endpoint. There is only one example with
recommendations regarding dimensions to be included
(cardiac failure); only two questionnaires are cited (Min-
nesota Living with Heart Failure, St. George’s Respira-
tory Questionnaires); there are no comments on the issue
of generic/specific instruments, and no recommendations
in expected diseases/drugs (i.e., hypertension).
CONCLUSION: Our review showed that QoL is not for-
mally recognized as a criterion of evaluation by the EMEA,
and recommendations are not consistent across documents.
Further collaboration between regulatory bodies and QoL
researchers is needed to improve the quality of recommen-
dations.
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OBJECTIVE: To compare the performance of a generic
measure (EuroQoL EQ-5D) and condition-specific mea-
sures (GHQ-12, HADS, and SCL-90) in measuring men-
tal health outcomes.
METHODS: Patients from three separate studies were
identified: 1) dental patients attending for treatment (n 
600); 2) psychiatric patients taking part in an RCT of
psychotherapy (n  104); and 3) patients in an observa-
tional study in rheumatoid arthritis (RA) (n  233). Pa-
tients receiving dental treatment also complete the GHQ-12
(a measure of psychiatric “caseness”). Psychiatric patients
in the interventional study were assessed using SCL-90 at
baseline and again at 3 and 6 months. RA patients com-
pleted HADS at baseline, 3 months, and 12 months. All
patients completed EQ-5D on one or more occasions.
The performance of EQ-5D was tested in terms of its ca-
pacity to discriminate between groups with known differ-
ences in mental health status, and to detect significant
clinical change over time.
RESULTS: Dental patients who screened positive on the
GHQ-12 differed significantly in terms of their EQ-5D
from patients who did not. RA patients with well sepa-
rated HAD scores were found to differ significantly in
terms of EQ-5D. In the psychotherapy study, patients
with poor levels of general health status on admission re-
ported significant improvement; above average patients
reported significant deterioration. Correlation between
EQ-5D and SCL-90 subscales was significant.
